Conflicts of Interest: Drs. Lipton and Sheftell have received research funding from Merck and have acted as paid consultants for Merck.
Moving Forward – Essential Questions for the Next 10 Years
Article first published online: 21 JAN 2009
© 2009 the Authors. Journal compilation © 2009 American Headache Society
Headache: The Journal of Head and Face Pain
Special Issue: 10 Years of Rizatriptan
Volume 49, Issue Supplement s1, pages S43–S46, February 2009
How to Cite
Lipton, R. B. and Sheftell, F. D. (2009), Moving Forward – Essential Questions for the Next 10 Years. Headache: The Journal of Head and Face Pain, 49: S43–S46. doi: 10.1111/j.1526-4610.2008.01362.x
- Issue published online: 21 JAN 2009
- Article first published online: 21 JAN 2009
- Accepted for publication November 3, 2008.
- migraine science;
- future direction;
The future is bright for migraine sufferers. For acute treatment, CGRP antagonists and combination products will provide more complete, longer lasting, and safer relief. “Designer drugs” for migraine prevention will be identified based on their ability to block cortical spreading depression and will improve migraine treatment. Genetic and environmental risk factors that promote migraine progression will be identified and preventing progression will become a standard goal in treatment. Some of the devices intended to treat migraine will be approved and will provide important options for sufferers seeking to avoid drugs. Clinical trials that evaluate behavioral and pharmacologic interventions and their impact on patient centered outcomes will emerge. The emergence of novel treatments, when coupled with strategies for individualizing and optimizing treatment while maximizing adherence, will result in ever improving patient outcomes.